Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy

被引：0
|
作者：
Prithviraj, Prashanth
McArthur, Grant A.
Atkinson, Victoria
Parente, Phillip
Andrews, Miles Cameron
Parakh, Sagun
Cebon, Jonathan S.
Klein, Oliver
机构：
[1] Austin Hlth, Med Oncol Unit, Heidelberg, Vic, Australia
[2] Peter MacCallum Canc Ctr, East Melbourne, Australia
[3] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia
[4] Monash Univ, Box Hill Hosp, Eastern Hlth Clin Sch, Melbourne, Vic 3004, Australia
[5] Austin Hosp, Heidelberg, Vic, Australia
[6] Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9059
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    Bowyer, S.
    Prithviraj, P.
    Lorigan, P.
    Larkin, J.
    McArthur, G.
    Atkinson, V.
    Millward, M.
    Khou, M.
    Diem, S.
    Ramanujam, S.
    Kong, B.
    Liniker, E.
    Guminski, A.
    Parente, P.
    Andrews, M. C.
    Parakh, S.
    Cebon, J.
    Long, G. V.
    Carlino, M. S.
    Klein, O.
    BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
  • [2] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    S Bowyer
    P Prithviraj
    P Lorigan
    J Larkin
    G McArthur
    V Atkinson
    M Millward
    M Khou
    S Diem
    S Ramanujam
    B Kong
    E Liniker
    A Guminski
    P Parente
    M C Andrews
    S Parakh
    J Cebon
    G V Long
    M S Carlino
    O Klein
    British Journal of Cancer, 2016, 114 : 1084 - 1089
  • [3] Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’
    Keisuke Imafuku
    Koji Yoshino
    Kei Yamaguchi
    Satoshi Tsuboi
    Kuniaki Ohara
    Hiroo Hata
    British Journal of Cancer, 2017, 116 : e14 - e14
  • [4] Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
    Imafuku, Keisuke
    Yoshino, Koji
    Yamaguchi, Kei
    Tsuboi, Satoshi
    Ohara, Kuniaki
    Hata, Hiroo
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e14 - e14
  • [5] Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
    Bowyer, Samantha
    Prithviraj, Prashanth
    Lorigan, Paul
    Larkin, James
    McArthur, Grant
    Atkinson, Victoria
    Millward, Michael
    Khou, Muoi
    Diem, Stefan
    Ramanujam, Sangeetha
    Kong, Ben
    Liniker, Elizabeth
    Guminski, Alexander
    Parente, Phillip
    Andrews, Miles C.
    Parakh, Sagun
    Cebon, Jonathan
    Long, Georgina V.
    Carlino, Matteo S.
    Klein, Oliver
    BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e15 - e15
  • [6] Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
    Samantha Bowyer
    Prashanth Prithviraj
    Paul Lorigan
    James Larkin
    Grant McArthur
    Victoria Atkinson
    Michael Millward
    Muoi Khou
    Stefan Diem
    Sangeetha Ramanujam
    Ben Kong
    Elizabeth Liniker
    Alexander Guminski
    Phillip Parente
    Miles C Andrews
    Sagun Parakh
    Jonathan Cebon
    Georgina V Long
    Matteo S Carlino
    Oliver Klein
    British Journal of Cancer, 2017, 116 : e15 - e15
  • [7] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [8] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [9] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [10] Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
    Savoia, Paola
    Astrua, Chiara
    Fava, Paolo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (05) : 1092 - 1101
12345